ID: h-3c562f5aff
Hypothesis
Reactive astrocytes and cholinesterase-rich low-acetylcholine niches amplify tau progression
Reactive astrocytes may degrade acetylcholine and destabilize cortical network states, secondarily creating conditions permissive for tau phosphorylation and spread.
EvidencePending (0%)📖 1 cit🗣 1 debates✓ 3 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Reactive astrocytes may degrade acetylcholine and destabilize cortical network states, secondarily creating conditions permissive for tau phosphorylation and spread. The debate judged this as a secondary amplifier at best, not a primary ordering mechanism.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Neuroinflammatory Trigger<br/>Amyloid or Injury"]
B["Reactive Astrocyte<br/>Activation A1 State"]
C["BCHE ACHE Cholinesterase<br/>Overexpression"]
D["Acetylcholine Degradation<br/>Cholinergic Deficit"]
E["Cortical Network<br/>Destabilization"]
F["GSK3B CDK5 Kinase<br/>Activation"]
G["Tau Phosphorylation<br/>Neurofibrillary Tangles"]
H["Secondary Tau Spread<br/>Cognitive Decline"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
G --> H
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style B fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix3 supports2 contradicts
Supports
Reactive astrocytes and cholinesterase in Alzheimer's disease brain.
Supports
The Role of Butyrylcholinesterase and Iron in the Regulation of Cholinergic Network and Cognitive Dysfunction in Alzheimer's Disease Pathogenesis.
Supports
Glial-derived proteins activate cultured astrocytes and enhance beta amyloid-induced glial activation.
Contradicts
Timing and causality are unclear, and astrocyte cholinesterase changes may be compensatory or downstream of existing pathology.
Contradicts
Organoid systems poorly capture mature extracellular acetylcholine dynamics and may overstate apparent rescue by cholinesterase inhibition.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — BCHE
No curated PDB or AlphaFold mapping for BCHE yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for BCHE, ACHE, GSK3B, CDK5 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for BCHE, ACHE, GSK3B, CDK5.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.3%
Volatility
Low
0.0155
Events (7d)
2
Price History
▲10.3%💾 Resource Usage
LLM Tokens
19,162
$0.0575
Total Cost
$0.0575
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF chemogenetic (hM3Dq) activation of astrocytes is induced in 5xFAD mice crossed with P301S-tau mice for 4 weeks to elevate local cholinesterase expression, THEN cortical acetylcholine levels will de | ≥40% decrease in ACh concentration (microdialysis); ≥50% increase in AT8+ tau pathology in activated cortical regions | — no observation — | pending | 0.35 |
| IF selective astrocyte-targeted BCHE/ACHE inhibition (via AAV-shBCHE microinjection into entorhinal cortex) is performed in P301S tauopathy mice at 3 months, THEN tau phosphorylation at AT8+ sites and | ≥30% reduction in AT8+ immunoreactive neurons in hippocampus and entorhinal cortex; decreased NFT burden in hippocampus | — no observation — | pending | 0.40 |
🔮 Falsifiable Predictions (2)
pendingconf 40%
IF selective astrocyte-targeted BCHE/ACHE inhibition (via AAV-shBCHE microinjection into entorhinal cortex) is performed in P301S tauopathy mice at 3 months, THEN tau phosphorylation at AT8+ sites and hippocampal tau spread will be reduced by ≥30% at 6 months compared to control AAV-treated mice.
Predicted outcome: ≥30% reduction in AT8+ immunoreactive neurons in hippocampus and entorhinal cortex; decreased NFT burden in hippocampus
Falsification: No significant difference in AT8+ signal or NFT count between BCHE/ACHE inhibition group and controls (p>0.05)
pendingconf 35%
IF chemogenetic (hM3Dq) activation of astrocytes is induced in 5xFAD mice crossed with P301S-tau mice for 4 weeks to elevate local cholinesterase expression, THEN cortical acetylcholine levels will decrease by ≥40% and AT8+ tau pathology will increase by ≥50% in activated versus DTA-inactivated cont
Predicted outcome: ≥40% decrease in ACh concentration (microdialysis); ≥50% increase in AT8+ tau pathology in activated cortical regions
Falsification: No change in ACh levels or no increase in tau pathology in activated regions (ACh decrease <20%, AT8+ change not significant)
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.